Sirolimus in Kidney Transplant Patients With Squamous Cell Skin Carcinoma

Stopped early · Phase 2

Conditions studied: Squamous Cell Skin Carcinoma

In brief

Solid organ transplant recipients (SOTR) have a 3-5x increased occurrence of cancer in contrast to the general population with basal and squamous cell skin cancer. The use of immunosuppressant or anti-rejection drugs that are needed after SOTR is known to increase the risk of developing certain kinds of cancer. The purpose of this study is to find out how well Sirolimus (also known as Rapamune) works at treating squamous cell carcinoma in renal transplant patients.

Key facts

Study ID

NCT01764607

Run by

University of Florida

People needed

1

Starts

2013-04-01

Expected to finish

2014-06-01

Last updated by the study team

2018-11-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically proven squamous cell skin carcinoma
• Recipient of a renal organ transplant at least one year prior to study enrollment
• Receiving a CNI for at least 6 months prior to diagnosis of skin cancer
• No current evidence of graft rejection, except low-grade, chronic graft rejection
• Measurable disease by caliper measurement
• Life expectancy > 6 months
• Age of at least 18 years
• Adequate organ and marrow function as determined by ANC, HGB, PLT, Total Bili, AST, and creatinine clearance
• Ability to understand/willingness to sign a written informed consent form

You may not qualify if…

• Inability to give informed consent
• Major surgery within 4 week prior to starting study drug
• Chronic or non-healing open wounds
• Pregnant and nursing women
• Women and men of child-bearing potential must agree to use adequate contraception prior to study entry and for the study duration
• Prior use of an mTOR inhibitor
• Pre-existing clinically significant cardiac, hepatic, pulmonary, or renal dysfunction
• HIV-positive patients
• Proteinuria (> 1 gram)
• Prior or current history of uncontrolled hyperlipidemia (cholesterol > 302 mg/dl or triglycerides 354 mg/dl
• Currently receiving any investigational agents
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to sirolimus (mTOR inhibitors)
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrythmia, or psychiatric illness/social situations that would limit compliance with study requirements

Where it is running

• Shands at the University of Florida — Gainesville, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.